RxSight (RXST) Q4 2025: LAL Mix Hits 86% as LDD Sales Drop 64%, Shifting Margin Profile
LAL, or Light Adjustable Lens, mix surged to a record 86% of sales in Q4, but this shift was driven by a steep LDD, or Light Delivery Device, sales decline, exposing RxSight’s dependence on procedure volume over capital placements. Management’s 2026 guide signals a reset, with near-term revenue contraction and gross margin compression, while betting on utilization gains and international groundwork to reignite growth in 2027. Investors face a business in transition, with operational discipline and innovation pacing the path to durable premium IOL, or intraocular lens, leadership.
Summary
- LAL Revenue Mix Reaches New High: High-margin LALs now dominate sales mix, but capital device placements fell sharply.
- Margin Pressures Surface: Manufacturing absorption and lower LDD volumes pull gross margin outlook below recent highs.
- International Expansion Lays Foundation: Measured global entry and clinical validation are central to long-term growth strategy.
Performance Analysis
RxSight’s Q4 2025 results marked a pivotal shift in its revenue composition, with LALs accounting for 86% of total sales, up from 71% a year ago. This was not driven by explosive lens growth, but rather a steep drop in LDD placements, which fell from 83 units and $11 million last year to just 25 units and $3 million this quarter. The company’s installed LDD base, however, expanded 17% year-over-year, now exceeding 1,100 units globally, suggesting a larger potential procedure pool for future LAL utilization.
Gross margin rose to 77.5% in Q4 due to the high LAL revenue mix, but management guided 2026 margins down to 70–72%—a reset reflecting the sell-through of higher-cost inventory and ongoing manufacturing absorption headwinds. Operating expenses were tightly managed, with SG&A and R&D both down year-over-year, though full-year opex still grew 11% as RxSight invested in commercial and R&D initiatives. The company ended the year with a net loss, but a strong cash position of $228 million and no debt provides flexibility as it navigates a transitional year.
- Device Sales Volatility: LDD sales fell 64% YoY, underscoring the lumpy nature of capital placements compared to recurring lens revenue.
- Procedure Volume Resilience: LAL unit sales were flat YoY but up 10% sequentially, signaling stabilization and opportunity to drive utilization.
- Operating Discipline: SG&A and R&D costs declined in Q4, reflecting management’s focus on efficiency amid revenue headwinds.
Full-year sales grew 4%, but this masked a 48% collapse in LDD revenue offset by 12% growth in LALs. The company’s future now rests on driving higher lens utilization per installed device and leveraging its installed base, rather than relying on capital sales spikes.
Executive Commentary
"Although the full-year financial results were below our initial expectations, 2025 was a year of meaningful progress for RxSight, for which I want to thank our 500 employees and thousands of customers, as together we advanced the delivery of our life-changing LAL technology around the world."
Dr. Ron Kurtz, President and Chief Executive Officer
"Full-year revenue guidance of $120 to $135 million implies a year-over-year decline of approximately 5% at the midpoint of the range, primarily driven by lower LDD sales versus the year-ago period. We anticipate a rebound in total company sales growth in the second half of the year as growth comparisons ease and commercial initiatives begin to gain traction."
Mark Wilterding, Chief Financial Officer
Strategic Positioning
1. Installed Base Leverage
RxSight’s installed LDD base surpassed 1,100 units, giving it a significant embedded opportunity to drive recurring LAL sales. Management’s commercial focus is shifting from aggressive device placements to increasing lens utilization within existing practices, supported by targeted education and workflow optimization. This pivot is designed to stabilize revenue and reduce reliance on lumpy capital sales cycles.
2. Margin Management Amid Inventory Headwinds
Gross margin guidance for 2026 was set well below 2025 levels, reflecting the impact of higher-cost inventory from reduced production and a greater mix of lower-margin LDD sales in the second half. Management is taking a prudent approach to margin forecasting, with expectations for recovery as manufacturing absorption normalizes and lens mix improves in future years.
3. International Expansion as Long-Term Catalyst
The company is laying groundwork for global growth, with recent regulatory approvals in the EU, UK, South Korea, Singapore, and Australia. The focus for 2026 is on building local clinical data and key opinion leader networks, with only modest revenue expected in the near term. China and Japan remain longer-term opportunities, pending regulatory progress.
4. Innovation and Portfolio Expansion
RxSight maintains a rapid pace of product innovation, with more than 20 FDA approvals in the past five years and additional submissions planned. The company is advancing features like Active Shield, LAL+, and expanded IOL powers, while also updating its LDD and insertion device platforms. This ongoing innovation is critical for maintaining differentiation in the premium IOL segment.
5. Commercial Execution and Practice Engagement
Management is investing in structured training and support programs to deepen engagement with existing practices. Early signs of improved LAL utilization are emerging, but leadership acknowledges that sustained commercial effort is required, with ongoing, rather than one-time, interventions tailored to practice needs.
Key Considerations
RxSight’s Q4 and full-year results highlight a business at an inflection point, as it transitions from rapid capital placement growth to a model emphasizing recurring lens sales and utilization. The company’s ability to drive same-store sales and leverage its installed base is central to future growth, while international expansion and innovation provide longer-term upside.
Key Considerations:
- Sales Mix Shift: LALs now dominate revenue, but this is partially due to a sharp LDD sales decline, not just lens growth.
- Gross Margin Compression: 2026 guidance reflects manufacturing absorption and inventory headwinds, with normalization expected beyond this year.
- International Ramp Is Methodical: Modest OUS revenue expected in 2026, with groundwork for a more significant contribution in 2027 and beyond.
- Innovation Pipeline Remains Robust: Multiple product enhancements and regulatory filings planned, supporting long-term differentiation.
- Commercial Discipline Over Blitz Expansion: Focused practice engagement and utilization improvement replace prior emphasis on rapid device placements.
Risks
RxSight faces near-term risks from a contracting LDD market, margin pressure due to higher-cost inventory, and the need to drive higher utilization per device to offset lower capital sales. Competitive launches in the premium IOL space could challenge adoption, while international expansion may be slower than anticipated due to regulatory or market hurdles. Management’s prudent guidance reflects these uncertainties, but execution risk remains elevated in a transitional year.
Forward Outlook
For Q1 2026, RxSight expects:
- Seasonally lowest sales, with LDD placements and LAL volumes at trough levels.
- Gross margin potentially above full-year range as lower-cost inventory is sold through.
For full-year 2026, management guided:
- Revenue of $120 to $135 million, a 5% YoY decline at midpoint, mainly due to lower LDD sales.
- Gross margin of 70% to 72%, below 2025’s high but in line with 2024 levels.
- Operating expenses of $150 to $160 million, reflecting continued investment in commercial and international initiatives.
Management highlighted:
- Expected sales rebound in the second half as comps ease and commercial actions gain traction.
- International sales to remain modest, with foundational work ongoing for a larger 2027 contribution.
Takeaways
RxSight is navigating a deliberate transition from device-led to utilization-driven growth, with margin headwinds and revenue contraction expected in the near term. The company’s ability to leverage its installed LDD base, drive same-store sales, and execute on international and innovation strategies will determine its long-term premium IOL leadership.
- Revenue Composition Shift: High LAL mix signals a maturing installed base but exposes the business to utilization risk as capital placements slow.
- Margin Reset Is Temporary: Manufacturing absorption and inventory dynamics are expected to normalize, with higher margins achievable as lens mix improves and international ramps.
- Execution Watchpoint: Investors should monitor lens utilization per device, commercial engagement effectiveness, and the pace of international adoption for signs of sustainable growth reacceleration.
Conclusion
RxSight’s Q4 2025 results and 2026 outlook reflect a business recalibrating for sustainable, utilization-led growth. While near-term headwinds persist, the company’s installed base, innovation cadence, and measured international expansion position it for durable premium IOL market leadership if execution aligns with potential.
Industry Read-Through
The premium IOL segment is showing signs of resilience, with RxSight’s performance indicating that procedural volume can offset capital equipment volatility when utilization is prioritized. Competitors launching new multifocal and presbyopia-correcting IOLs may see similar adoption curve challenges, reinforcing the importance of clinical validation and practice engagement. Margin dynamics across ophthalmic device makers will likely remain sensitive to inventory and manufacturing absorption, especially as product mix shifts from capital sales to recurring procedure revenue. International expansion strategies in medtech will hinge on local clinical champions and tailored go-to-market models, with regulatory timelines as a gating factor for global growth acceleration.